Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Posts Higher Q1 Loss on Lower Revenues

Premium

MDRNA last week reported a jump in its first-quarter loss as a drop in revenues more than offset a decrease in operating costs.

MDRNA's net loss in the quarter was $9.5 million, or $0.20 per share, versus a year-ago loss of $7.3 million, or $0.23 per share.

Revenues in the quarter plummeted $14 million to $200,000, reflecting the receipt of milestones and licensing fees from partners Novartis, Roche, and Amylin Pharmaceuticals in the year-ago quarter, which were not received this year.

Research and development spending in the first quarter dropped about 13 percent, to $3.6 million from $4.1 million, reflecting patent license fees paid in the period last year that did not recur the following year.

Selling, general, and administrative costs, meanwhile, rose to $2.6 million from $2.1 million.

As of March 31, MDRNA had cash and cash equivalents totaling $3.8 million.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.